Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1183/13993003.02604-2017 | DOI Listing |
Microvasc Res
December 2024
Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O. box 400, Woldia, Ethiopia; Research Center for Tuberculosis and Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Prinshof, 0084 Pretoria, South Africa.
Background: Diabetes mellitus (DM) is a metabolic abnormality affecting 537 million people worldwide. Poor glycemic control, longer duration, and poor medication adherence increased the risk of DM complications. Comprehensive evidence on the pooled prevalence of microvascular complications in DM patients in Ethiopia is not available.
View Article and Find Full Text PDFInt J Mycobacteriol
October 2024
Department of Pulmonary Medicine, Medical College, Baroda and SSGH, Vadodara, Gujarat, India.
Background: Extrapulmonary tuberculosis (EP-TB) constitutes one-fifth of all tuberculosis (TB) cases. EP-TB mimics common infections which pose diagnostic dilemma, requires extensive diagnostics that culminate into therapeutic delay often resulting in irrational and empirical institution of antitubercular therapy (ATT) in challenging cases. This supplemented by poor treatment compliance resulted in emergence of Drug-resistant (DR) strains of EP-TB which further impedes the path to recovery.
View Article and Find Full Text PDFJ Cell Biol
January 2025
Host Pathogen Interactions in Tuberculosis laboratory, The Francis Crick Institute, London, UK.
Like other organelles, the heterogeneity of lysosomes within a single cell has been challenging to capture and study in detail. In this issue, Chen and Gutierrez discuss new work that tackles this question using DNA-PAINT imaging, from Lakadamyali and colleagues (https://doi.org/10.
View Article and Find Full Text PDFBMJ Open
December 2024
Department of Public Health, Sefako Makgatho Health Sciences University Faculty of Health Sciences, Pretoria, South Africa.
Introduction: Tuberculosis (TB) is a significant public health crisis in Africa. TB control programmes implemented by various state and non-state actors in different African countries over the years have recorded significant gains in the reduction of the incidence and prevalence of TB through the vehicle of private care provider engagement in the diagnosis, treatment and care. However, the corporate sector, which often represents a large pool of resources and access to individuals, is neglected or underestimated in the public-private mix of TB control efforts.
View Article and Find Full Text PDFExpert Opin Pharmacother
December 2024
Department of Respiratory Functional Exploration, University Medical Centre, University of Medicine and Pharmacy, Ho Chi Minh city, Vietnam.
Introduction: Pulmonary fibrosis (PF) post-COVID-19 has been identified as an important complication of Long-COVID, especially in patients with severe respiratory symptoms. High-resolution computed tomography (HRCT) is the main tool for detecting fibrotic lesions in patients with PF post-COVID-19.
Areas Covered: We conducted a systematic review with the following objectives: (1) to summarize the incidence and disease burden of post‑COVID‑19 pulmonary fibrosis, (2) to provide information on available therapies and drugs for its management, (3) to comprehensively evaluate the initial treatment efficacy of these drugs, and (4) to identify the limitations and challenges associated with current treatment approaches.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!